The psychotropic drug dopamine PET study

Not Applicable

• Conditions: healthy

• Registration Number: JPRN-jRCTs031190184
• Lead Sponsor: Yoshiro Okubo

Brief Summary

Sertlarine occupied almost 20% of dopamine transporter in striatum. While tramadol and placebo did not effect on dopamine transporter.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-01-20
• Study Completion: 2020-02-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 2

Inclusion Criteria

1) Subjects who are 20 years old or older and younger than 40 years old when obtaining consent
2) Subjects with no hisotry of psychiatric disorders
3) Subjects with normal BMI (18.5-25)
4) Subjects without the history of smoking
5) Subjects who have the ability to provide informed consent and adhere to the protocol.

Exclusion Criteria

1) Subjects with drug allergy
2) Subjects who have gastrointestinal symptoms when taking lactose
3) Subjects taken contraindications for the study drug within 2 weeks prior to obtaining consent
4) Subjects who is contrainidicated for the use of MRI
5) Subjects with the history of smoking, or who took cafefin (by 2 days before PET), or alcohol (by the day before PET)
6) Athletes at the competition level
7) Subjects who has been exposed to radiation by job-related exposure or therapy in one year exceeding 15mSv
8) Subjects who do not agree to notify the results of the examination which requires treatment.
9) Subjects who are judged as not suitable for participation in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the change of binding potential of dopamin transporter

Secondary Outcome Measures

Name	Time	Method
blood drug concentration<br>evaluation of higher brain function (neuropsychological examination)